SERN | Southeast NBS & Genetics Regional Collaborative

Like us on Facebook! Follow SERC_Genetics on Twitter Subscribe to our RSS Feed
Login | Contact Us

COVID-19 is an emerging, rapidly evolving situation.

Sarah Young, PhD

Sarah Young, PhD   
Contact Information
(919) 549-0445 Main Office

Log in to view additional contact information.

Roles
Biochem Lab
Diagnostic Lab Director

Centers & Contact Information
Biography
Sarah Young is an Assistant Professor in the Department of Pediatrics, in the Duke School of Medicine, and Co-Director of the Duke Biochemical Genetics Laboratory. She graduated from the Manchester University, UK with a degree in Biochemistry in 1993 and completed a Ph.D. in Biochemistry in 1998 at the Institute of Child Health, University College London. She has worked at the Duke School of Medicine since 1999, completing a fellowship in Clinical Biochemical Genetics in 2005. Her main research interest is the development and application of biomarker assays for rare, inherited metabolic disorders that will improve diagnosis of these conditions, and are useful for monitoring treatments. This includes neurometabolic disorders such as the creatine deficiency syndromes. These disorders can be diagnosed using liquid chromatography-tandem mass spectrometric assays that measure biomarkers in urine and plasma. Additionally, more rapid methods have been developed using tandem mass spectrometry that can be used for newborn screening.

Education

1993 Biochemistry B.Sc. (Hons) University of Manchester, U.K.

1998 Biochemistry Ph.D. University College London, U.K.

2005 ABMG certification in Clinical Biochemical Genetics

Selected Publications
  1. El-Gharbawy A.H., Goldstein J.L., Millington D.S., Vaisnins A.E., Schlune A., Barshop B.A., Schulze A.,Koeberl D.D., Young S.P. (2013) Elevation of Guanidinoacetate in Newborn Dried Blood Spots and Impact of Early Treatment in GAMT Deficiency, Mol Genet Metab. 109:215-7.
  2. Manoli I, Sysol JR, Li L, Houillier P, Garone C, Wang C, Zerfas PM, Cusmano-Ozog K, Young S, Trivedi NS, Cheng J, Sloan JL, Chandler RJ, Abu-Asab M, Tsokos M, Elkahloun AG, Rosen S, Enns GM, Berry GT, Hoffmann V, DiMauro S, Schnermann J and Venditti CP (2013) Targeting proximal tubule mitochondrial dysfunction attenuates the renal disease of methylmalonic acidemia. . Proc Natl Acad Sci USA. 110:13552-7. doi: 10.1073/pnas.1302764110.
  3. Farah BL, Madden L, Li S, Nance S, Bird A, Bursac N, Yen PM, Young SP and Koeberl DD (2014) Adjunctive beta2-agonist treatment reduces glycogen independently of receptor-mediated acid alpha-glucosidase uptake in the limb muscles of mice with Pompe disease. FASEB J 28:2272-80.
  4. Koeberl DD, Austin S, Case LE, Smith EC, Buckley AF, Young SP, Bali D and Kishnani PS (2014) Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease. FASEB J 28:2171-6
  5. Houten SM, Denis S, te Brinke H, Jongejan A, van Kampen AHC, Bradley EJ, Baas F, Hennekam RCM, Millington DS, Young SP, Frazier DM, Gucsavas-Calikoglu M and Wanders RJA (2014) Mitochondrial NADP(H) deficiency due to a mutation in NADK2 causes dienoyl-CoA reductase deficiency with hyperlysinemia. Hum Mol Genet.23:5009-16.
  6. Zhang H, Wood T, Young SP, Millington DS. (2015) A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: An improved clinical screening test for the mucopolysaccharidoses. Mol Genet Metab.114:123-8
  7. Prasun P, Young S, Salomons G, Werneke A, Jiang YH, Struys E, Paige M, Avantaggiati ML, McDonald M. (2015) Expanding the Clinical Spectrum of Mitochondrial Citrate Carrier (SLC25A1) Deficiency: Facial Dysmorphism in Siblings with Epileptic Encephalopathy and Combined D,L-2-Hydroxyglutaric Aciduria. JIMD Rep.19:111-5.
  8. Chien Y-Y, Goldstein JL, Hwu W-L, Smith PB, Lee NC, Chiang SC, Tolun AA, Zhang H, Vaisnins AE, Millington DS, Kishnani PS, Young SP. (2015) Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile and Late-Onset Pompe Disease Identified by Newborn Screening JIMD Rep.19:67-73.
  9. Nilsson MI, MacNeil LG, Kitaoka Y, Suri R, Young SP, Kaczor JJ, Nates NJ, Ansari MU, Wong T, Ahktar M, Brandt L, Hettinga BP, Tarnopolsky MA Combined aerobic exercise and enzyme replacement therapy rejuvenates the mitochondrial-lysosomal axis and alleviates autophagic blockage in Pompe disease. Free Radic Biol Med. 2015 May 19. pii: S0891-5849(15)00230-0. doi: 10.1016/j.freeradbiomed.2015.05.019. [Epub ahead of print]PMID: 26001726

SERN Highlights
July 2020

A Taste of eGNA: Now Expanding with Project ECHO

A Taste of eGNA: Now Expanding with Project ECHO

The Southeast Regional Genetics Network (SERN) is ready to launch its first Project ECHO platform for genetic disorders. Our first pilot project will focus on a multidisciplinary medical education approach focused on training genetic metabolic providers. We are currently recruiting for the Genetic Nutrition ECHO program which will launch in the fall of 2020. We hosted an ECHO methodology demonstration on Wednesday, April 29 where more than 300 genetic professionals, public health professionals, and other providers registered to learn more about Project ECHO. We had three case presenters from different institutions, active audience participation, and faculty experts who provided recommendations. If you are a genetic professional, currently seeing patients, we would like your help in completing the Genetic Nutrition ECHO Needs Assessment.

In addition, if you are interested in further educational opportunities, you will be directed to complete the Participant Interest Form after completing the needs assessment, which the ECHO team will use to enroll the first trainee cohort for the program and interested members will be provided with more details. For any further questions please contact egna@emory.edu.

Home | About | Contact Us
This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $600,000.00 with 0 percent financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.

© 2006-2017   —   SOUTHEAST REGIONAL GENETICS NETWORK   —   A HRSA SUPPORTED PARTNERSHIP   —   GRANT #UH7MC30772